2. Gene
  3. RALY - RALY heterogeneous nuclear ribonucleoprotein Gene

RALY - RALY heterogeneous nuclear ribonucleoprotein Gene

  • 基因
  • 蛋白
  • 疾病
  • 相关产品
  • 直系同源

中文名称：RALY 异质核核糖核蛋白

种属: Homo sapiens

同用名: P542; HNRPCL2

基因 ID: 22913 | 基因类型: protein coding

关于 RALY

Cytogenetic location: 20q11.22 Genomic coordinates (GRCh38): 20:33,993,911-34,084,884 (from NCBI)

This gene has 10 transcripts (splice variants), 203 orthologues and 6 paralogues. Ubiquitous expression in bone marrow (RPKM 18.7), testis (RPKM 18.3) and 25 other tissues.

功能概要

该基因编码异质核核糖核蛋白 (hnRNP) 基因家族的成员。这种蛋白质可能在 pre-mRNA 剪接和胚胎发育中发挥作用。交替剪接导致多个转录本变体。[RefSeq 提供，2011 年 9 月]

This gene encodes a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) gene family. This protein may play a role in pre-mRNA splicing and in embryonic development. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Sep 2011]

RALY 基因产物(2)

mRNA Protein Name
NM_007367.4 NP_031393.2 RNA-binding protein Raly isoform 2
NM_016732.3 NP_057951.1 RNA-binding protein Raly isoform 1
基因本体论
  • 分子功能
  • 细胞组分
分子功能 GO 注释 逻辑证据 参考文献 来源
enables protein binding IPI
IPI: 通过物理相互作用推断
22365833 GOA
细胞组分 GO 注释 逻辑证据 参考文献 来源
part of catalytic step 2 spliceosome IDA
IDA: 通过直接分析推断
11991638 GOA
located in nucleus IDA
IDA: 通过直接分析推断
22720776 GOA
EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

RALY 蛋白结构

RRM_1

RRM_1: RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain) (23 - 85)

  • 0
  • 100
  • 200
  • 306 a.a.
蛋白主名 其他名称

RNA-binding protein Raly

RNA binding protein, autoantigenic (hnRNP-associated with lethal yellow homolog)

RALY 蛋白互作信息

分类
蛋白名称 蛋白编号 互作蛋白 互作蛋白种属 互作蛋白编号 实验方法 参考文献
Intra RALY Q9UKM9 HNRNPC Homo sapiens P07910
Crosslink
30021884
Intra RALY Q9UKM9 HNRNPC Homo sapiens P07910
Y2H
22365833
Intra RALY Q9UKM9 HNRNPC Homo sapiens P07910
Anti Tag CoIP
33961781
Intra RALY Q9UKM9 FUS Homo sapiens P35637
PLA
30354839
Intra RALY Q9UKM9 FUS Homo sapiens P35637
IF
30354839
Intra RALY Q9UKM9 FUS Homo sapiens P35637
Anti Tag CoIP
30354839
Intra RALY Q9UKM9 HNRNPCL2 Homo sapiens B2RXH8
Crosslink
30021884
种属间: 跨种属相互作用 种属内: 同种属相互作用

关联疾病

疾病名称 别名
Skin Carcinoma In Situ

Carcinoma In Situ Of Skin

Cutaneous Carcinoma In Situ
Bardet-Biedl Syndrome 1

BBS1

Bardet-Biedl Syndrome 1, Modifier Of

Bardet-Biedl Syndrome

BBS

Bardet-Biedl Syndrome, Type 1

Laurence-Moon-Bardet-Biedl Syndrome
疾病名称 别名
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

相关产品

Approval
生物活性分子 (10)
目录号 产品名 作用方式
纯度 是否罕见病
HY-15771 Tirabrutinib 99.65% 是
HY-P3502 Zilucoplan Inhibitor 95.33% 否
HY-10405 Pamapimod Inhibitor 99.92% 否
HY-15771A Tirabrutinib hydrochloride 99.43% 是
HY-B0524 Betahistine Modulator 98.04% 否
HY-B0524A Betahistine dihydrochloride Modulator 99.82% 否
HY-106019 Liarozole Inhibitor 98.83% 是
HY-110159 (E/Z)-Teriflunomide Inhibitor ≥95.0% 是
HY-D0237 Betahistine mesylate Modulator 99.90% 否
HY-B0160 Lafutidine Antagonist 99.95% 否
抗体抑制剂 (2)
目录号 产品名 作用方式
纯度 是否罕见病
HY-P9924 Ixekizumab Inhibitor 98.90% 否
HY-P99661 Inbakicept Activator 98.95% 否
Clinical Phase
生物活性分子 (8)
目录号 产品名 作用方式
纯度 Phase
HY-10291 Tarenflurbil Inhibitor 99.96% Phase 3
HY-106019C Liarozole dihydrochloride Inhibitor ≥99.0% Phase 3
HY-14531 Talarozole Inhibitor 99.61% Phase 2
HY-18099A S1RA hydrochloride Antagonist 99.94% Phase 2
HY-147264 Edecesertib Inhibitor 99.86% Phase 2
HY-18099 S1RA Antagonist 99.43% Phase 2
HY-101671 S-methyl-KE-298 ≥98.0% Phase 2
HY-103169 SCH442416 Antagonist 99.68% Phase 1
抗体抑制剂 (7)
目录号 产品名 作用方式
纯度 Phase
HY-P99210 Olokizumab Inhibitor 95.85% Phase 3
HY-P99252 Itolizumab ≥99.0% Phase 3
HY-P99259 Cabiralizumab Inhibitor 99.59% Phase 2
HY-P99870 Eblasakimab ≥99.0% Phase 2
HY-P99940 Remtolumab Inhibitor 99.24% Phase 2
HY-P99385 Vobarilizumab Inhibitor 97.36% Phase 2
HY-P99642 Gimsilumab Inhibitor / Phase 2
Pre-clinical Phase
生物活性分子 (118)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-N0142 Phloretin Inhibitor 99.67% 否
HY-125099A AFM-30a hydrochloride Inhibitor 99.96% 否
HY-108521 HX531 99.87% 否
HY-147141 HS-276 Inhibitor 98.59% 否
HY-P0204A Endothelin-3, human, mouse, rabbit, rat TFA 99.51% 否
HY-111532 (3R,4R)-A2-32-01 Inhibitor 99.73% 否
HY-15898 Y-320 99.74% 否
HY-108522 PA452 Antagonist ≥99.0% 否
HY-100739 RA190 Inhibitor 99.09% 否
HY-110275 RA839 98.90% 否
HY-50081 CCR2-RA-[R] Antagonist 99.71% 否
HY-N2435 [8]-Shogaol 99.93% 否
HY-147972 NF-κB/MAPK-IN-1 Inhibitor 98.42% 否
HY-118530 Bucillamine Inhibitor 98.87% 是
HY-136528 RA-9 98.67% 否
HY-136563 RA375 99.31% 否
HY-N1976 (+)-(3R,8S)-Falcarindiol Inhibitor 98.53% 否
HY-W008388 Bz-rA 99.51% 否
HY-N1440 Koumine Activator 99.97% 否
HY-21545 5'-O-DMT-Bz-rA ≥98.0% 否
HY-103046 UbcH5c-IN-1 Inhibitor 99.84% 否
HY-103175 PSB36 Antagonist ≥99.0% 否
HY-N4260 Ginsenoside Ra2 95.95% 否
HY-147660 IMMH001 Agonist 98.10% 否
HY-125415 PF-4693627 Inhibitor 99.63% 否
HY-N2506 Ginsenoside Ra1 99.77% 否
HY-139314 A2B receptor antagonist 2 Antagonist 99.39% 否
HY-21703 3'-TBDMS-Bz-rA Phosphoramidite 98.38% 否
HY-103174 MRS1334 Antagonist ≥99.0% 否
HY-125099 AFM-30a Inhibitor ≥96.0% 否
HY-164416 DBCO-Dextran sulfate (MW 40000) 98.35% 否
HY-N10790 RA-V 99.63% 否
HY-N4259 Ginsenoside Ra3 98.24% 否
HY-W018179 5'-DMT-3'-TBDMS-Bz-rA 99.19% 否
HY-W006102 Bz-rA Phosphoramidite 97.58% 否
HY-104017 DMT-2'-O-MOE-rA(Bz) phosphoramidite ≥98.0% 否
HY-P3491 Pegloxenatide Agonist 90.00% 否
HY-W114886 DMT-OMe-rA(Bz) ≥97.0% 否
HY-W141394 Bz-OMe-rA 99.25% 否
HY-U00449G AGN 193109 (GMP) Antagonist / 否
HY-100707 IC 86621 Inhibitor 99.06% 否
HY-103177 PSB-10 hydrochloride Inhibitor / 否
HY-106019A Liarozole hydrochloride Inhibitor / 否
HY-106618 Mopidamol Inhibitor / 否
HY-107495 Betahistine EP Impurity C Modulator / 否
HY-107644 AQ-RA 741 Antagonist / 否
HY-107730 NPY5RA-972 Antagonist 98.86% 否
HY-117019 LY150310 free base / 否
HY-118689 RA-2 Modulator / 否
HY-120785A SR1555 hydrochloride Antagonist / 否
HY-126640 Phomoxanthone A Inhibitor / 否
HY-127150 Clofezone / 否
HY-135376 Atorvastatin methyl ester / 否
HY-135378 Atorvastatin ethyl ester / 否
HY-135453 (-)-Pinocembrin Inhibitor / 否
HY-139654 α/β-Hydrolase-IN-1 Inhibitor / 否
HY-143290 Antibacterial agent 118 Inhibitor / 否
HY-146104 Antimycobacterial agent-1 Inhibitor / 否
HY-14750 Rabeximod / 否
HY-149064 Antituberculosis agent-9 Inhibitor / 否
HY-149581 DprE1-IN-9 Inhibitor / 否
HY-150658S DMT-2′O-TBDMS-rA(ac)-1-15N phosphoramidite / 否
HY-151472 hCAIX/XII-IN-6 Inhibitor / 否
HY-152035 Mycobacterial Zmp1-IN-1 Inhibitor / 否
HY-153333 A1/A3 AR antagonist 3 Antagonist / 否
HY-154961 Mcl-1 inhibitor 14 / 否
HY-154962 Mcl-1 inhibitor 15 Inhibitor / 否
HY-155031 MCI Inhibitor / 否
HY-163533 CPD-002 Inhibitor / 否
HY-163750 KMU-11342 / 否
HY-167905 ATL444 Antagonist / 否
HY-B0160S Lafutidine-d10 Antagonist / 否
HY-B0524AS Betahistine-d3 dihydrochloride Modulator ≥99.0% 否
HY-B0524AS1 Betahistine-13C,d3 dihydrochloride Modulator / 否
HY-D2279 NFL-NH2 / 否
HY-N0142R Phloretin (Standard) Inhibitor / 否
HY-N10793 RA-XI / 否
HY-N11646 Ganorbiformin B Inhibitor / 否
HY-N11650 (22S,24E)-3β,22-Diacetoxylanosta-7,9(11),24-trien-26-oic acid Inhibitor / 否
HY-N11957 Angeloylbinankadsurin A / 否
HY-N12015 Ginsenoside Ra6 / 否
HY-N12648 Anemarsaponin E1 / 否
HY-N3612 Communic acid Inhibitor / 否
HY-P10292 NOTA-Pep-1L / 否
HY-P3502A Zilucoplan TFA Inhibitor / 否
HY-RS03232 CSF2RA Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS06673 IL10RA Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS06676 IL11RA Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS06688 IL13RA1 Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS06689 IL13RA2 Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS06693 IL15RA Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS06702 IL17RA Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS06732 IL20RA Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS06737 IL22RA1 Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS06738 IL22RA2 Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS06747 IL27RA Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS06748 IL2RA Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS06755 IL31RA Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS06764 IL3RA Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS06773 IL5RA Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS11635 RALY Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-U00449A AGN 193109 sodium Antagonist / 否
HY-105934A Ketotrexate sodium / 否
HY-113721 BML-244 Inhibitor / 否
HY-116472 alpha-RA-F / 否
HY-118761 5,6-Epoxyretinoic acid / 否
HY-119291 RA642 / 否
HY-121435 K-8012 / 否
HY-123019 RA-263 / 否
HY-125068 RPR203494 Inhibitor / 否
HY-126862 AQ-RA 721 / 否
HY-13496 JNJ-28312141 Inhibitor / 否
HY-137007 SMA-12b Inhibitor / 否
HY-161762 RA-0002034 Inhibitor / 否
HY-162707 RA-0002323-01 / 否
HY-18016 CGI 560 Inhibitor / 否
HY-N2876 Anisofolin A Inhibitor / 否
HY-U00420 Opioid receptor modulator 1 Modulator / 否
抗体抑制剂 (9)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-P99287 Elsilimomab Inhibitor 98.44% 否
HY-P990016 Temtokibart Inhibitor 99.23% 否
HY-P9923A Benralizumab (anti-IL5RA ) 99.60% 否
HY-P99487 Briobacept 97.66% 否
HY-P990086 Vopikitug Inhibitor / 否
HY-P99782 Opinercept Inhibitor / 否
HY-P990713 Nolavetbart / 否
HY-P990719 Efbalropendekin alfa / 否
HY-P990776 Vimekofusp / 否

直系同源

种属 基因名 来源 基因 ID
Mus musculus RALY MGD MGI:97850
Bos taurus RALY VGNC VGNC:33706
Rattus norvegicus RALY RGD RGD:1307228
Canis familiaris RALY VGNC VGNC:45337
Felis catus RALY VGNC VGNC:81167
Macaca mulatta RALY VGNC VGNC:76486
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z